Current status of cationic liposome-mediated gene therapy in cystic fibrosis

Allesia Colosimo, Federica Sangiuolo, Sabrina Di Sario, Paola Amicucci, Anna Lucia Serafino, Antonio Novelli, Margherita Sabani, Massimo Castro, Vincenzina Lucidi, Giuseppe Mossa, Bruno Dallapiccola, Giuseppe Novelli

Research output: Contribution to journalArticlepeer-review

Abstract

Gene therapy is actually seen as a useful approach to the treatment of a wide range of diseases, including single-gene disorders and polygenic diseases of multifactorial ethiology. Cystic fibrosis (CF), one of the most common single-gene diseases, has become a main target for treatments by somatic gene therapy. Human clinical trials have been performed in the past five years, using cationic liposome and adenovirus as vectors. The cationic liposome approach and the current progress in CF gene therapy are here briefly reviewed.

Original languageEnglish
Pages (from-to)221-227
Number of pages7
JournalActa Pharmaceutica
Volume48
Issue number4
Publication statusPublished - Dec 1998

Keywords

  • Cationic liposomes
  • Cystic fibrosis
  • Gene therapy
  • Human clinical trials

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Current status of cationic liposome-mediated gene therapy in cystic fibrosis'. Together they form a unique fingerprint.

Cite this